Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis.

TitleSphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis.
Publication TypeJournal Article
Year of Publication2016
AuthorsSasset, L, Zhang, Y, Dunn, TM, Di Lorenzo, A
JournalTrends Endocrinol Metab
Volume27
Issue11
Pagination807-819
Date Published2016 11
ISSN1879-3061
KeywordsAnimals, Cardiovascular Diseases, Homeostasis, Humans, Lysophospholipids, Nogo Proteins, Sphingolipids, Sphingosine
Abstract

Sphingolipids (SL) are both fundamental structural components of the eukaryotic membranes and signaling molecules that regulate a variety of biological functions. The highly-bioactive lipids, ceramide and sphingosine-1-phosphate, have emerged as important regulators of cardiovascular function in health and disease. In this review we discuss recent insights into the role of SLs, particularly ceramide and sphingosine-1-phosphate, in the pathophysiology of the cardiovascular system. We also highlight advances into the molecular mechanisms regulating serine palmitoyltransferase, the first and rate-limiting enzyme of de novo SL biosynthesis, with an emphasis on the recently discovered inhibitors of serine palmitoyltransferase, ORMDL and NOGO-B proteins. Understanding the molecular mechanisms regulating this biosynthetic pathway may lead to the development of novel therapeutic approaches for the treatment of cardiovascular diseases.

DOI10.1016/j.tem.2016.07.005
Alternate JournalTrends Endocrinol. Metab.
PubMed ID27562337
PubMed Central IDPMC5075255
Grant ListR01 HL126913 / HL / NHLBI NIH HHS / United States